MEDIGARD BLOOD-DEVICE LAUNCH HITS A SNAG

Written on the 15 May 2015 by Jenna Rathbone

MEDIGARD BLOOD-DEVICE LAUNCH HITS A SNAG

MEDIGARD'S (ASX:MGZ) unique blood collection device is yet to hit shelves, despite two announcements that initial sales for the medical instrument would commence in March of this year.

The Gold Coast company, which has again delayed the launch, says it is a result of market resistance to primary packaging and unexpected delays occurring while trying to implement a solution.

Although significant resources had been employed to produce a blood collection device (BCD) that requires no primary packaging, it is now expected that sales for the BCD will commence in June.

Medigard says at the time of announcing a March launch date it was convinced the changes made to the device to allow it to be manufactured and distributed without primary packaging would not cause significant further delays.

"Although the changes are not obvious from appearance, the subtle design changes and the changes to the materials used for the moulding of some key components has also meant that manufacturing equipment has had to be modified," says Medigard in a statement to shareholders.

"As is the nature of medical device design changes, there has had to be changes to the regulatory approvals for the BCD.  Both of these factors have caused unexpected delays."

Small-scale manufacture is currently under way and the BCD is expected to launch in Taiwan and Asia Pacific in June and the US and Europe in July.

Medigard says 300,000 BCDs are currently in production and will be distributed for clinical evaluations. A clinical study is to be coordinated in the UK.

The Medigard BCD features vacuum technology to capture the needle after blood has been collected.  This is expected to prevent needle-stick injury by eliminating human contact with used needles and avoids potential aerosoling, a dangerous spray of fluid getting into the air when a needle is retracted.

In 2013, Medigard secured an exclusive license agreement with Shanghai Sol-Millennium Medical Products Co to manufacture and distribute its BCD and Blood Flash Needle.

Medigard has patents for the BCD in Australia, the US, Japan, Canada and Europe while the 3ml vacuum retractable syringe has patents in South Africa, the US, Australia, China, Japan and Canada.

Medigard was floated in 2004 and its board includes Don Channer as chairman and Peter Clark as director.

Shares closed at .085c. 


Author: Jenna Rathbone
About: Jenna Rathbone is a Queensland-based journalist who writes on a range of issues including business and property affairs and social issues.
Connect via: Twitter

Latest News

BRISBANE VFX PRODUCTION COMPANY CLEANS UP AT MAJOR INTERNATIONAL ADVERTISING AWARDS

AUSTRALIAN production company Alt.vfx has broken records in global advertising, becoming the first business to win...

CYCLONE DEBBIE FORCES MINE, RAIL AND PORT CLOSURES AS IT WREAKS HAVOC IN QUEENSLAND

COAL and gold mines in north and central Queensland are being seriously impacted as Cyclone Debbie makes landfall ...

FLYING START TO 2017 PASSENGER NUMBERS FOR GOLD COAST AIRPORT

RECORD numbers of travellers used the Gold Coast Airport (GCA) in January this year, continuing a five-year trend ...

SUNCORP SAYS IT'S 'COVERED' AGAINST FINANCIAL COST OF CYCLONE DEBBIE

INSURER Suncorp (ASX: SUN) says it is "well protected" against the financial impact of Cyclone Debbie th...

Related News

RAY OF HOPE FOR SLATER AND GORDON AS LENDERS STEP IN

EMBATTLED law firm Slater and Gordon (ASX: SGH) has announced to the ASX that it has launched confidential discussion...

SPROUTX PROVIDES THE SEED FOR AGTECH STARTUPS

AGTECH innovation fund SproutX has opened applications for its first accelerator round, backed by $10 million from...

GAS PRICES MAY FORCE BRICKWORKS TO TAKE MANUFACTURING OVERSEAS

BRICKWORKS Limited (ASX:BKW) chairman Robert Millner says soaring energy prices may force the company to turn to offs...

CHINA CONTINUES TO COLLECT AUSSIE PROPERTY ASSETS

CHINESE coin continues to dominate Australia's offshore real estate investment market, accounting for almost h...

EVENTS COMING UP

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter